Menu Philippe sold $28K of SOPH

Menu Philippe (Chief Medical Officer) sold 5,000 shares of SOPHiA GENETICS SA (SOPH) at $5.66 on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Menu Philippe
Published Jul 28, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 28, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SOPH
Neutral
high confidence
Mentioned
$SOPH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHNeutralLow
01

Why it matters

The newest concrete fact is the specific open-market sale size, price, and total value, but it is explicitly under a pre-arranged 10b5-1 plan, reducing interpretive weight.

02

Market read

Traders may note the insider sale for sentiment monitoring, but it is unlikely to drive a fundamental repricing without additional company-specific catalysts.

03

What to watch

The article provides no context on whether the sale was part of a larger scheduled program, nor any concurrent operational updates, limiting inference.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-28, transaction dated 2026-07-27.

Background

The article is a SEC Form 4 insider transaction disclosure for SOPHiA GENETICS SA, reported by its Chief Medical Officer.

Company-level read

Ticker impact

$SOPHNeutralHigh confidence
Context

SOPHiA GENETICS Form 4 shows CMO Menu Philippe sold 5,000 shares on 2026-07-27 at $5.6611, totaling $28,305.50.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely muted.

Evidence & confidence

The filing is an insider transaction, explicitly tied to a pre-arranged Rule 10b5-1 plan, and the disclosed value is modest relative to typical market-moving thresholds.

Market effects

Minimal. No sector-wide regulatory, clinical, or commercial update is disclosed.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution; traders may still watch for follow-on disclosures.

Key entities

  • SOPHiA GENETICS SA

    Company whose Form 4 insider transaction is disclosed.

  • Menu Philippe

    Chief Medical Officer who sold 5,000 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

$SOPHMed

SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary

SOPHiA GENETICS reported Q3 2026 U.S. revenue growth of 41%, driven by improved reimbursement and lower sequencing costs. Liquid Biopsy volume surged over 100% YoY, led by the MSK-ACCESS product. The company projects full-year 2026 revenue at the upper end of $94M-$96M range, with 2027 revenue highly visible. Management expects positive adjusted EBITDA in H2 2027. The Unified Patent Court rejected Guardant Health's appeal, confirming no injunction against MSK-ACCESS.

$SOPHMed

SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA (SOPH) reported Q3 2026 earnings, highlighting 19% growth in platform analyses to 118,000. U.S. revenue grew 41%, driven by new accounts and expanding services. Liquid Biopsy tests saw 100% year-on-year growth. The company also announced collaborations with BioPharma firms, including a top 10 company for bladder cancer research and AstraZeneca for companion diagnostics.

$SOPHMed

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September